TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-22.83%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$220M
AUM Growth
+$220M
(-13%)
Cap. Flow
+$26.5M
Cap. Flow
% of AUM
12.05%
Top 10 Holdings %
Top 10 Hldgs %
98.43%
Holding
15
New
10
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$4.88M |
| 2 |
Alibaba
BABA
|
$4.74M |
| 3 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$3.76M |
| 4 |
Opko Health
OPK
|
$3.64M |
| 5 |
Nektar Therapeutics
NKTR
|
$3.58M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 85.52% |
| 2 | Consumer Discretionary | 2.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Heron Therapeutics
HRTX
$207M
| $98.6M | 44.89% | 5,190,837 | – | – |
|
|
LJPC
2
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $63.8M | 29.06% | 3,052,130 +180,000 | +6% | +$3.76M |
|
3
BioMarin Pharmaceuticals
BMRN
$11.2B
| $7.44M | 3.39% | 90,215 | – | – |
|
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $4.88M | 2.22% | +250,000 | New | +$4.88M |
|
|
5
Alibaba
BABA
$322B
| $4.74M | 2.16% | +60,000 | New | +$4.74M |
|
|
6
Opko Health
OPK
$1.1B
| $3.64M | 1.66% | +350,000 | New | +$3.64M |
|
|
7
Nektar Therapeutics
NKTR
$568M
| $3.58M | 1.63% | +260,000 | New | +$3.58M |
|
|
INFI
8
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $2.42M | 1.1% | +460,000 | New | +$2.42M |
|
9
BioCryst Pharmaceuticals
BCRX
$1.74B
| $1.22M | 0.55% | +430,000 | New | +$1.22M |
|
10
Lipocine
LPCN
$15.8M
| $1.02M | 0.46% | +100,000 | New | +$1.02M |
|
|
ATYR
11
aTyr Pharma
ATYR
$527M
| $749K | 0.34% | +190,000 | New | +$749K |
|
|
RXDX
12
DELISTED
Ignyta, Inc.
RXDX
| $271K | 0.12% | +40,000 | New | +$271K |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $189K | 0.09% | +50,000 | New | +$189K |
|